ITERUM THERAPEUTICS PLC (ITRM) Stock Price, Forecast & Analysis
USA - NASDAQ:ITRM - IE000TTOOBX0 - Common Stock
ITRM Key Statistics, Chart & Performance
The current stock price of ITRM is 0.6049 USD. In the past month the price decreased by -18.47%. In the past year, price decreased by -56.79%.
ITRM Latest News, Press Relases and Analysis
ITRM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.78 | 3.97B |
Related stock screener links
About ITRM
Company Profile
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 9 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives. The company offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The firm operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Company Info
ITERUM THERAPEUTICS PLC
3 Dublin Landings, North Wall Quay
DUBLIN DUBLIN 2 IE
CEO: Corey N. Fishman
Employees: 9
Phone: 35319038354
ITERUM THERAPEUTICS PLC / ITRM FAQ
What does ITERUM THERAPEUTICS PLC do?
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 9 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives. The company offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The firm operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Can you provide the latest stock price for ITERUM THERAPEUTICS PLC?
The current stock price of ITRM is 0.6049 USD. The price increased by 3.79% in the last trading session.
Does ITRM stock pay dividends?
ITRM does not pay a dividend.
How is the ChartMill rating for ITERUM THERAPEUTICS PLC?
ITRM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about ITERUM THERAPEUTICS PLC (ITRM) stock?
8 analysts have analysed ITRM and the average price target is 7.14 USD. This implies a price increase of 1080.36% is expected in the next year compared to the current price of 0.6049.
What is the Price/Earnings (PE) ratio of ITERUM THERAPEUTICS PLC (ITRM)?
ITERUM THERAPEUTICS PLC (ITRM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.83).
What is ITERUM THERAPEUTICS PLC worth?
ITERUM THERAPEUTICS PLC (ITRM) has a market capitalization of 29.07M USD. This makes ITRM a Nano Cap stock.
ITRM Technical Analysis
ITRM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ITRM. ITRM may be in some trouble as it scores bad on both profitability and health.
ITRM Financial Highlights
Over the last trailing twelve months ITRM reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS increased by 58.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.77% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ITRM Forecast & Estimates
8 analysts have analysed ITRM and the average price target is 7.14 USD. This implies a price increase of 1080.36% is expected in the next year compared to the current price of 0.6049.